Clinical Trial Update: A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV) [Phase 1]

View source ↗

Summary

Phase 1 Thorough QT study of CHF5993 delivered via metered-dose inhaler in healthy volunteers to assess potential effects on the QT interval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF5993 pMDI (CHF5993)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Status: COMPLETED